Insider Selling: Stoke Therapeutics (NASDAQ:STOK) CFO Sells 2,382 Shares of Stock

Key Points

• CFO Thomas Leggett sold 2,382 shares on March 18 at an average price of $31.34 (about $74,652) after selling 2,196 shares on March 17, leaving him with 10,172 shares — an approximate 18.97% reduction in his ownership.
• Stoke shows mixed signals: multiple analysts have raised price targets and pipeline optimism around STK‑001, but the latest quarter missed expectations (EPS $(0.97) vs. $(0.75) and revenue $1.4M vs. $5.3M), creating near‑term investor concern despite bullish analyst sentiment.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) CFO Thomas Leggett sold 2,382 shares of the firm's stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $74,651.88. Following the sale, the chief financial officer owned 10,172 shares of the company's stock, valued at $318,790.48. This represents a 18.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Thomas Leggett also recently made the following trade(s):

• On Tuesday, March 17th, Thomas Leggett sold 2,196 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total value of $72,489.96.

Stoke Therapeutics Price Performance

STOK traded up $2.17 on Thursday, reaching $33.19. The company's stock had a trading volume of 853,428 shares, compared to its average volume of 754,489. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $40.22. The business's 50 day moving average is $32.61 and its 200 day moving average is $29.90. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed "buy" with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics in the 3rd quarter worth about $1,062,000. Marshall Wace LLP grew its position in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company's stock valued at $26,111,000 after buying an additional 168,771 shares during the last quarter. Penserra Capital Management LLC bought a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at about $3,539,000. Franklin Resources Inc. raised its stake in Stoke Therapeutics by 264.8% during the second quarter. Franklin Resources Inc. now owns 81,395 shares of the company's stock worth $924,000 after acquiring an additional 59,081 shares during the period. Finally, Vanguard Group Inc. raised its stake in Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company's stock worth $74,351,000 after acquiring an additional 217,616 shares during the period.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wedbush raised their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an "outperform" rating in a research report on Tuesday. Guggenheim assumed coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They set a "buy" rating and a $60.00 price objective on the stock. Weiss Ratings reissued a "hold (c-)" rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Wolfe Research started coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They issued an "outperform" rating and a $40.00 target price for the company. Finally, BTIG Research restated a "buy" rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $39.83.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.